AJOVista’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

AJOVista’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,544	Closed	-$20.7K	–	456
2023 Q4	$20.7K	Buy	+1,544	New	+$19.5K	0.03%	356

Other funds holding MACK

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AJOVista's MACK Position: Q1 2024 in Review

AJOVista sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2024, closing a stake of 1,544 shares — an estimated $20.7K sold.

AJOVista first reported a position in MACK in Q4 2023 and held it in 1 quarter. The position peaked at $20.7K in Q4 2023. 70 funds tracked by Wall St. Rank hold MACK as of Q1 2024.

AJOVista reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
AJOVista sold 1,544 Merrimack Pharmaceuticals, Inc. shares in Q1 2024, an estimated $20.7K.
AJOVista first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2023 and held it in 1 quarter.
AJOVista's Merrimack Pharmaceuticals, Inc. position peaked at $20.7K in Q4 2023.
70 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2024.

Based on AJOVista's 13F filing for Q1 2024, filed 10 May 2024.